04:58 AM EST, 11/13/2026 (MT Newswires) -- SynAct Pharma (SYNACT.ST) received a notice of allowance from the US Patent and Trademark Office for a patent covering an immediate-release solid oral dosage formulation of resomelagon in clinical testing. The patent for resomelagon tablet is expected to be granted within a few weeks, according to a Friday release. The biotechnology company already has two US patents covering the crystal form of resomelagon, an oral selective melanocortin agonist to treat rheumatoid arthritis and certain viral infections.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.